United States Platelet Rich Plasma Market

Market Overview:

The United States platelet rich plasma market size reached US$ 249.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 546.2 Million by 2032, exhibiting a growth rate (CAGR) of 8.8% during 2024-2032.

Platelet-rich plasma (PRP) refers to a concentrated plasma protein that contains minor quantities of red blood cells. The platelets are suspended in a small amount of plasma after centrifugation and stimulate healing when injected into the body. PRP is widely administered by non-invasive therapies for long-lasting rejuvenation of ligaments and muscle fibers. Some of the common variants of PRP include pure platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (LPRP), leukocyte- and platelet-rich Fibrin (L-PRF), and pure platelet-rich fibrin (P-PRF).

The rising prevalence of chronic tendon injuries in vital organs is currently bolstering the demand for PRP-based therapies in the US. Furthermore, increasing adoption of effective therapies for treating muscle and acute ligament tearing, arthritis, fractures, orthopedic impairments, etc., is also propelling the market growth. In line with this, the growing awareness towards numerous benefits of PRP treatment in preventing inflammation, encouraging new cartilage formulation, and inducing natural lubrication fluid production, is further augmenting the product demand in the country. Moreover, the rising deployment of advanced healthcare facilities for sports clubs and teams is also catalyzing the adoption of PRP-based therapies for treating common injuries in athletes, such as lumbar spine disc pain, rotator cuff injuries, shoulder pain and instability, tennis/golfer’s elbow, etc. Apart from this, the expanding cosmetic surgery sector in the United States is further driving the utilization of PRP-based procedures for improving facial shape and volume. In the coming years, the increasing healthcare expenditures along with the rising demand for non-invasive medical procedures will continue to spur the demand for PRP-based therapies in the United States.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the United States platelet rich plasma market report, along with forecasts at the country level from 2024-2032. Our report has categorized the market based on product type, origin, application, and end user.

Breakup by Product Type:

• Pure Platelet-Rich Plasma (P-PRP)
• Leukocyte- and Platelet-Rich Plasma (LPRP)
• Leukocyte- and Platelet-Rich Fibrin (L-PRF)
• Pure Platelet-Rich Fibrin (P-PRF)
   

Breakup by Origin:

• Autologous PRP
• Homologous PRP
• Allogeneic PRP
   

Breakup by Application:

• Orthopedics
• Cosmetic Surgery and Dermatology
• Neurosurgery
• General Surgery
• Cardiothoracic Surgery
• Urology
• Ophthalmology
• Others
   

Breakup by End User:

• Hospitals and Clinics
• Research Institutes
• Others
   

Breakup by Region:

• Northeast
• Midwest
• South
• West
   

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Arteriocyte Medical Systems Inc. (Isto Technologies II LLC), Arthrex Inc., Depuy Synthes, Inc. (Johnson & Johnson), Dr Prp USA LLC, EmCyte Corporation, Exactech Inc., Glofinn America LLC (Glofinn Co. Ltd.), Regen Lab USA LLC, Stryker Corporation, Terumo BCT Inc. (Terumo Corporation), ThermoGenesis Holdings Inc. and Zimmer Biomet Holdings Inc.

Report Coverage: